Compare · NBIX vs OPT

NBIX vs OPT

Side-by-side comparison of Neurocrine Biosciences Inc. (NBIX) and Opthea Limited (OPT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NBIX and OPT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • NBIX carries a market cap of $16.73B.
  • NBIX has hit the wire 11 times in the past 4 weeks while OPT has been quiet.
  • NBIX has more recent analyst coverage (25 ratings vs 6 for OPT).
MetricNBIXOPT
Company
Neurocrine Biosciences Inc.
Opthea Limited
Price
-
-
Market cap
$16.73B
-
1M return
+21.71%
-
1Y return
+15.02%
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
1996
2020
News (4w)
11
0
Recent ratings
25
6
NBIX

Neurocrine Biosciences Inc.

Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

OPT

Opthea Limited

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Latest NBIX

Latest OPT